Thevetin

Thevetin is a cardiac glycoside extracted from *Thevetia peruviana*, known for its potent effects on heart function. It primarily inhibits the Na+/K+-ATPase pump, increasing intracellular calcium and enhancing myocardial contractility.

Origin & History

Thevetin is a cardenolide glycoside found in the highly poisonous plant Thevetia peruviana (yellow oleander), particularly concentrated in its seeds, fruits, and milky latex sap. Native to Central and South America but now widespread in tropical regions, it is extracted using methanol/water or ethanolic extraction methods from plant parts.

Historical & Cultural Context

Thevetin has been historically noted as a heart stimulant derived from Thevetia peruviana in traditional medicine systems. However, specific traditional medicine systems, preparation methods, or duration of use are not documented in available sources, with its use being overshadowed by its high toxicity rather than established therapeutic efficacy.

Health Benefits

• Cardiac stimulation properties similar to digitalis glycosides (Preliminary evidence - 1940s-1950s observational studies)
• Rapid onset positive inotropic effects on heart function (Preliminary evidence - PMID: 18885613)
• Potential enhancement of cancer cell apoptosis when combined with TNF-α and TRAIL (Preliminary evidence - in vitro studies only)
• Historically used for cardiac insufficiency treatment (Preliminary evidence - PMID: 13199422)
• May modulate cardiovascular response through Na+/K+-ATPase inhibition (Preliminary evidence - PMID: 13397252)

How It Works

Thevetin, like other cardiac glycosides, primarily inhibits the sarcolemmal Na+/K+-ATPase pump. This leads to intracellular sodium accumulation, reducing Na+/Ca2+ exchanger activity. The resulting increase in intracellular calcium enhances myocardial contractility and stroke volume.

Scientific Research

Clinical evidence for thevetin is extremely limited, with only early observational studies from the 1940s-1950s available. One study (PMID: 18885613) described thevetin as having digitalis-like properties with rapid onset, while another (PMID: 13199422) evaluated its use in cardiac insufficiency patients, though neither provided modern trial design details or sample sizes. No randomized controlled trials or meta-analyses exist for this compound.

Clinical Summary

Preliminary evidence from 1940s-1950s observational studies suggested Thevetin's cardiac stimulation, similar to digitalis. More recent research, including a study (PMID: 18885613), indicates rapid onset positive inotropic effects on heart function. Additionally, early in vitro/animal studies hint at enhancing cancer cell apoptosis with TNF-α. However, human clinical trial data is limited, and evidence for therapeutic use is largely preliminary and outdated.

Nutritional Profile

Thevetin is a toxic cardiac glycoside (specifically a mixture of thevetin A and thevetin B) extracted primarily from the seeds and other parts of the yellow oleander plant (Thevetia peruviana). As a cardenolide-type glycoside, it contains a steroidal aglycone (thevetigenin) linked to sugar moieties, structurally and pharmacologically similar to digitalis glycosides such as digoxin. It has no nutritional value and is considered highly poisonous, with its bioactivity centered on inhibition of the Na+/K+-ATPase pump in cardiac tissue.

Preparation & Dosage

No clinically studied dosage ranges for thevetin have been established due to its extreme toxicity. Animal toxicity studies used 0.5-3.0 g/kg body weight of T. peruviana dried fruit extract, which resulted in severe toxicity and organ damage. This compound should not be used as a supplement due to its poisonous nature. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

None - thevetin is toxic and should not be combined with any supplements

Safety & Interactions

Thevetin has a narrow therapeutic index, with significant cardiotoxicity risks including arrhythmias, heart block, nausea, and blurred vision at supra-therapeutic doses. It is contraindicated in individuals with certain cardiac conditions like severe bradycardia or high-grade AV block. Thevetin can interact with drugs affecting heart rhythm or potassium levels, increasing toxicity risk. Due to its high toxicity, it is unsafe during pregnancy, breastfeeding, and generally for self-medication, requiring strict medical supervision.